Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎

F. Palandri, G.A. Palumbo, A. Iurlo, N. Polverelli, G. Benevolo, M. Breccia, E. Abruzzese, M. Tiribelli, M. Bonifacio, A. Tieghi, A. Isidori, B. Martino, N. Sgherza, M. D'Adda, M. Bergamaschi, M. Crugnola, F. Cavazzini, C. Bosi, G. Binotto, G. AuteriR. Latagliata, A. Ibatici, L. Scaffidi, D. Penna, D. Cattaneo, F. Soci, M. Trawinska, D. Russo, A. Cuneo, G. Semenzato, F. Di Raimondo, F. Aversa, R.M. Lemoli, F. Heidel, M.L.B. Reggiani, D. Bartoletti, M. Cavo, L. Catani, N. Vianelli

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)248-255
Number of pages8
JournalSeminars in Hematology
Volume55
Issue number4
DOIs
Publication statusPublished - 2018

Keywords

  • hemoglobin
  • ruxolitinib, adult
  • aged
  • anemia
  • Article
  • drug efficacy
  • drug response
  • female
  • high risk patient
  • human
  • intermediate risk patient
  • International Prognostic Scoring System
  • leukocyte count
  • major clinical study
  • male
  • multicenter study
  • myelofibrosis
  • overall survival
  • phenotype
  • platelet count
  • polycythemia vera
  • priority journal
  • probability
  • prognosis
  • scoring system
  • survival rate
  • thrombocythemia
  • thrombocytopenia
  • validity

Cite this